scholarly journals Efficacy and Tolerability of a Novel Topical Treatment for Neck: A Randomized, Double-blind, Regimen-Controlled Study

2021 ◽  
Vol 20 (2) ◽  
pp. 184-191
Author(s):  
Elizabeth Makino ◽  
Kuniko Kadoya ◽  
Robin Chung ◽  
Lily Jiang ◽  
Mouna Mikati ◽  
...  
Keyword(s):  
Topical Treatment ◽  
Controlled Study ◽  
Double Blind

scholarly journals Actinic keratosis prevention – A double-blind, half-face interventional study with a topical treatment

2018 ◽  
Vol 9 (1) ◽  
pp. 1
Author(s):  
Elisabetta Sorbellini ◽  
Barbara Marzani ◽  
Daniela Pinto ◽  
Fabio Rinaldi
Keyword(s):  
Active Treatment ◽  
Actinic Keratosis ◽  
Topical Treatment ◽  
Aminolevulinic Acid ◽  
Recurrent Disease ◽  
Controlled Study ◽  
Interventional Study ◽  
Lesion Formation ◽  
Double Blind ◽  
History Of

Actinic keratosis (AK) is a chronic and recurrent disease and in this double-blind, half face, placebo controlled study we attempt to examine the efficacy of a topical treatment containing 2,4,6-octatrienoic acid and anthraquinone knipholone for the prevention of new AK lesion formations. New lesion onset was detected with  methyl-5-aminolevulinic acid and Wood’s lamp after 6 months of treatment (T1) and 12 months after treatment end (T2). Absence of new lesion at T1, was 86.11% in active treatment side while 77.78% in placebo side. At T2 the percentage was higher in skin treated with active product  (83.33% of subjects) compared to placebo (63.89% of subjects).Taking into consideration the number of new lesions during the study period, at T1 the new AK lesions were not statistically significantly influenced by the treatments, while at T2, AK lesions were detected in 30.55% of placebo-treated area while in the contralateral part the lesions were 13.89%.  The reduction induced by active treatment was statistically significant.The product containing 2,4,6-octatrienoicienoic acid and anthraquinone knipholone is effective in reducing new AK lesion formation in subjects with a history of AKs.  

Topical treatment of CIN 2+ by cidofovir: Results of a phase II, double-blind, prospective, placebo-controlled study

2009 ◽  
Vol 115 (1) ◽  
pp. 69-74 ◽  
Author(s):  
C. Van Pachterbeke ◽  
D. Bucella ◽  
S. Rozenberg ◽  
Y. Manigart ◽  
C. Gilles ◽  
...  
Keyword(s):  
Phase Ii ◽  
Topical Treatment ◽  
Controlled Study ◽  
Double Blind
Sign in / Sign up

Export Citation Format

Share Document